This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NPS Pharmaceuticals Inc (NPSP)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -13.50M -18.74M -36.27M -31.44M
Operating Gains/Losses 37.00K -4.00K 646.00K -3.75M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -11.32M -16.01M 18.66M -2.27M
(Increase) Decrease in Inventories 3.66M 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 11.86M 1.32M -3.42M 1.86M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital -1.80M -1.25M 84.00K -10.45M
Other Non-Cash Items -18.84M -29.20M -33.87M 27.56M
Net Cash From Continuing Operations -24.32M -60.99M -56.66M -17.73M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -24.32M -60.99M -56.66M -17.73M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 107.87M 119.51M 86.67M 119.33M
Purchases of Property, Plant & Equipment -1.14M -1.19M -3.41M -862.00K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -156.84M -124.81M -111.38M -119.20M
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -50.11M -6.49M -28.12M -729.00K
Issuance of Debt 0.00 0.00 145.00M 38.40M
Cash Used for Financing Activities
Issuance of Capital Stock 0.00 2.56M 108.16M 98.76M
Repayment of Long-Term Debt 0.00 0.00 -213.85M -50.66M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 108.12M 0.00 50.69M -9.13M
Net Cash From Financing Activities 108.12M 2.56M 90.00M 77.37M
Effect of Exchange Rate Changes 44.00K -10.00K 5.00K -15.00K
Net Change in Cash & Cash Equivalents 33.73M -64.93M 5.23M 58.89M
NPSP News

NPSP NPS Pharmaceuticals Inc

Analysts Ratings for NPSP

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 6 7 7 6
Moderate Buy 2 2 2 2
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET NPSP ANALYST REPORT

Brokerage Partners

NPSP Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs